Trevi Therapeutics (TRVI) Operating Income (2018 - 2025)

Trevi Therapeutics' Operating Income history runs 8 years deep, the most recent figure standing at -$10.2 million for Q4 2025.

• On a quarterly basis, Operating Income rose 16.52% year-over-year to -$10.2 million in Q4 2025; TTM through Dec 2025 was -$50.1 million, a 2.76% increase from a year earlier, with the FY2025 full-year figure at -$49.3 million, up 4.26% from the prior year.
• Operating Income improved to -$10.2 million in Q4 2025 per TRVI's latest filing, from -$13.9 million in the prior quarter.
• Across five years, Operating Income topped out at -$6.7 million in Q4 2022 and bottomed at -$14.1 million in Q3 2024.
• The 5-year median for Operating Income is -$8.9 million (2023), against an average of -$9.8 million.
• Across the five-year window, Operating Income rose 19.53% in 2022 and plunged 58.54% in 2024, its largest moves.
• Year by year, Operating Income stood at -$8.3 million in 2021, then rose by 19.53% to -$6.7 million in 2022, then tumbled by 34.19% to -$8.9 million in 2023, then tumbled by 37.05% to -$12.2 million in 2024, then gained by 16.52% to -$10.2 million in 2025.
• Per Business Quant, the three latest TRVI Operating Income figures stand at -$10.2 million (Q4 2025), -$13.9 million (Q3 2025), and -$13.7 million (Q2 2025).